André CABIE
University Hospital of Martinique · Centre Hospitalier Universitaire de Martinique · CHU de Martinique
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name André CABIE as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:02 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT04211649 · Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)University Hospital Center of Martinique · not yet recruiting · Mild Leptospirosis · study director
- N/ANCT03795376 · Dat'Aids PreventionDatAids · recruiting · HIV Prevention · principal investigator
- N/ANCT02898987 · Quality of Care in French HIV Infected PatientsDatAids · recruiting · HIV · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:02 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- 130 citationsRCR 5.1
- An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.Clin Microbiol Infect · 202190 citationsRCR 4.7
- 87 citationsRCR 4.2
- Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).J Antimicrob Chemother · 201968 citationsRCR 3.6
- Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.J Antimicrob Chemother · 201259 citationsRCR 1.9
- Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.J Antimicrob Chemother · 201043 citationsRCR 1.2
- Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.PLoS One · 201924 citationsRCR 1.1
- Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).J Antimicrob Chemother · 202014 citationsRCR 0.8
- A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.J Antimicrob Chemother · 200913 citationsRCR 0.3
- Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).Antimicrob Agents Chemother · 20139 citationsRCR 0.3